Bliss GVS Pharma · NSE: BLISSGVS · BSE: 506197
Q2 FY26 results · Jul–Sep 2025
Bliss GVS Pharma reported revenue from operations of ₹244.40 crore (up 12.3% from Q2 FY25) and net profit of ₹28.59 crore (up 11.3% from Q2 FY25) for Q2 FY26 (Jul–Sep 2025), on a consolidated basis.
| Item | Q2 FY26 | Q2 FY25 | YoY | Q1 FY26 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 244.40 | 217.68 | +12.3% | 207.47 | +17.8% |
| Other income | 20.18 | 5.04 | +300.6% | 35.45 | −43.1% |
| Total income | 264.58 | 222.72 | +18.8% | 242.92 | +8.9% |
| Profit before tax | 40.63 | 35.71 | +13.8% | 63.11 | −35.6% |
| Net profit for the period | 28.59 | 25.69 | +11.3% | 44.36 | −35.6% |
| Attributable to shareholders of the company | 27.25 | 24.26 | +12.3% | 43.04 | −36.7% |
| EPS, basic (₹) | 2.58 | 2.31 | +11.7% | 4.08 | −36.8% |
| Net margin (%) | 11.7 | 11.8 | 21.4 |
| Item | Q2 FY26 | Q2 FY25 | YoY | Q1 FY26 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 190.23 | 182.65 | +4.1% | 163.36 | +16.4% |
| Other income | 25.84 | 8.35 | +209.4% | 10.59 | +144.0% |
| Total income | 216.07 | 191.00 | +13.1% | 173.96 | +24.2% |
| Profit before tax | 33.46 | 23.89 | +40.0% | 30.56 | +9.5% |
| Net profit for the period | 24.79 | 17.04 | +45.5% | 21.05 | +17.8% |
| EPS, basic (₹) | 2.35 | 1.63 | +44.2% | 2.00 | +17.5% |
| Net margin (%) | 13.0 | 9.3 | 12.9 |
Consolidated
- Filed with BSE
- 06 Nov 2025, 22:15 IST
- Board meeting
- 06 Nov 2025
- Period
- 01 Jul 2025 to 30 Sep 2025
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 06 Nov 2025, 22:15 IST
- Board meeting
- 06 Nov 2025
- Period
- 01 Jul 2025 to 30 Sep 2025
- Review status
- Unaudited
- Source
- XBRL filing on BSE